Jazz Pharmaceuticals plc: Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023

Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia DUBLIN, May 31, 2023 /PRNewswire/

Related Keywords

United States ,Ireland ,Japan ,Dublin ,Washington ,Seattle ,Japanese ,American ,Andrean Flynn ,Kelvin Tan ,Kristin Bhavnani ,International Classification Of Sleep Disorders ,Drug Administration ,Unmet Public Health Problem ,Jazz Pharmaceuticals ,American Academy Of Sleep Medicine ,American Psychiatric Association ,World Idiopathic Hypersomnia Total Health ,Nasdaq ,Prnewswire Jazz Pharmaceuticals ,National Academies Press ,National Health Service ,Indian Journal Of Medical Research ,Us Drug Enforcement Agency ,Jazz Pharmaceuticals Inc ,United States Drug Enforcement Agency ,National Institute Of Neurological Disorders ,Head Of Global Corporate Communications ,Office Of Orphan Product Development ,Associated Professional Sleep Societies ,Session Title ,Clinical Burden ,Idiopathic Hypersomnia ,Low Sodium Oxybate ,Decentralized Recruitment Approach ,Disease Registry ,Pediatric Patients With ,Reported Sleep Quality ,People With ,Participants With Narcolepsy ,From Sodium Oxybate ,Orphan Drug Exclusivity ,Orphan Product Development ,Enforcement Agency ,Risk Evaluation ,Mitigation Strategy ,Safety Information ,Prescribing Information ,Boxed Warning ,Global Corporate ,Neurological Disorders ,Accessed May ,Sleep Medicine ,Sleep Deprivation ,Narcolepsy Disease ,International Classification ,Third Edition ,Statistical Manual ,Fifth Edition ,Opin Investig ,Palo Alto ,States Drug Enforcement ,Accessed September ,Jazz ,Pharmaceuticals ,Emonstrates ,Ontinued ,Leadership ,Sleep ,Medicine ,Data ,Presentations ,023 ,